ERC PLUS GRANTS

Expected Outcome: This action will establish a strategic European initiative to develop scalable, modular, and interoperable photonic quantum computing platforms. Proposals for this topic are expected to address and provide credible solutions to at least two major technical roadblocks currently limiting the advancement of photonic quantum computing such as: The lack of deterministic, high-efficiency photonic entanglement and loss-tolerant architectures suitable for fault-tolerant scaling The absence of a standardised, integrated control stack combining photonic hardware, firmware, and system software with reliable benchmarking across platforms Project results are expected to contribute to the following expected outcomes: By 2028, demonstration of a photonic NISQ processor with ≥100 photonic qubits, integrating deterministic single-photon sources, low-loss waveguides, on-chip detectors, and a firmware stack (scheduler, controller, compiler), validated via hardware-agnostic benchmarks and hybrid photonic-HPC applications demonstrating classical-quantum crossover By 2030, delivery of a full-stack, high-connectivity photonic quantum computer, with modular scalability, integrated…

Expected Outcome: Excellent capacities in research management are essential for institutions and national R&I systems to enhance their research excellence and capitalize on their R&I activities in a knowledge-based economy and society. The Research Management Facility aims at providing institutions in Widening countries that want to establish or upgrade their research management capacities with tailored support. The Research Management Facility also advises on an implementation strategy to introduce changes in the institutional set-up, in line with the ERA priorities. However, the action does not provide support for the implementation of the strategy. Strong research management ensures effective grant acquisition, resource allocation, compliance with funding regulations, and strategic planning. It supports high-quality research by streamlining administrative processes, facilitating interdisciplinary collaborations, attracting and retaining international high-profile researchers, and optimizing the use of research infrastructures. Proposals are expected to contribute to the following outcomes: Encourage the establishment of stronger research management capacities in Widening…

Expected Outcome: The Synergy action for Teaming Centres of Excellence (CoE) responds to the need to ensure the sustainability of CoE funded under the Teaming calls [1] . The establishment of CoE in Widening countries, supported by a significant investment in Horizon 2020 and Horizon Europe, has created new opportunities for scientific, societal, and economic impact. However, to fully capitalise on this investment and enhance the sustainability and international competitiveness of these CoE, it is essential to facilitate stronger collaboration and strategic joint initiatives among them. Proposals are expected to contribute to all the following outcomes: Stronger long-term collaboration among Teaming CoE through structured joint initiatives and clustering efforts to enhance mutual learning, resource sharing, and collective research and innovation capacity; Strategic transformation of R&I systems by enhancing institutional cooperation and supporting structural reforms at national and regional levels; Promotion of multidisciplinary and transnational cooperation that will enable CoE to address critical European and global challenges, and EU policy priorities; Promote ERA priorities…

Expected Outcome: Successful proposals will contribute to the implementation of the EU initiative on Biotechnology and Biomanufacturing, the EU Life Sciences Strategy, the updated EU Bioeconomy Strategy, the EU Biotechnology Act, the Clean Industrial Deal, the European Chemical Industry Action Plan and the upcoming EU Circular Economy Act. Projects results are expected to contribute to the following expected outcomes: Full industrial scale biorefinery and related value chain(s) for the sustainable production of bio-based products using biotech as a key enabling technology. Availability of bio-based products meeting market and technical performance requirements as relevant for their respective application areas. Improvement of sustainability, circularity and resource efficiency compared to relevant benchmark(s). Contribution to increasing the EU’s strategic autonomy, resilience and competitiveness. Scope: Biorefineries integrating biotechnologies, underpinned by sustainably sourced bio-based feedstock, have a huge potential to transform the EU manufacturing landscape, spurring socio-economic growth, fostering job creation and contributing to defossilisation of the EU…

Expected Outcome: This flagship pilot is the culmination of the entire activity catalogue carried out by the CCAM Partnership since its launch in 2021. It will combine in one project the most promising CCAM use-cases across three key domains, with the technological advancements from all its R&I clusters [1] supporting and enabling CCAM systems and services towards market uptake. This action is expected to contribute to all the following outcomes: Large-scale demonstrations of inclusive, user-oriented, and well-integrated CCAM systems and services for people and goods in mixed traffic through Field Operational Tests (FOTs), Technology Pilots, and Living Labs, building upon advanced and emerging SAE Level 2 systems to move towards SAE Level 3 and 4 functionalities, at multiple test sites and corridors showcasing CCAM potential [2] , for a minimum of 12 months. Validation of enabling technologies that facilitate the extension of Operational Design Domains (ODDs) in large-scale operations and enhance perception performance under poor lighting and adverse weather conditions in large-scale demonstrations and pilots. Assessment of deployment readiness and demonstration of technological…

Expected Outcome: Proposals are expected to contribute to all following points: The projects must fulfil the performance targets, at the cell and system level, corresponding to the specific targeted application, to be specified in the proposal. Appropriate KPI must be defined for the energy density (volumetric and gravimetric), Power density and C-rate, number of cycles and cost defined under operational conditions. Boost EU competitiveness in next-generation battery technologies for mobility applications. Develop pilot manufacturing capability for next generation lithium-based batteries. Strengthen the EU battery value chain, including new manufacturing equipment, automation, and scalable production processes. Advance the understanding of next-generation battery interfaces at an industrial scale, ensuring manufacturability, durability, and cost-effectiveness. In the case of aviation, the battery requirements should be compatible at minimum with EASA CS.23 (level 4), CS.27 and preferably with CS.25 categories. Scope: This topic will support the scaling-up of next generation (i.e., beyond generation 3) lithium-based batteries (e.g., semi and all-solid state, generation5) from cell…

Scope: Objectives The Starting Grant supports excellent Principal Investigators starting or having recently started their own independent research team or programme. A Starting Grant Principal Investigator should have already shown evidence of the potential for research independence, for example, by having produced at least one important publication as its main author or a publication without the participation of their PhD supervisor. A researcher may be the Principal Investigator of only one ERC Starting Grant in their career. Size of ERC Starting Grants Starting Grants may be awarded up to a maximum of EUR 1 500 000 for a period of 60 months . The maximum amount of the grants is reduced pro rata temporis for proposals of shorter duration. Additional funding up to EUR 1 000 000 *1 can be requested to cover further eligible costs for any cost category when these are necessary to carry out the proposed work. The request for additional funding must be duly justified in the proposal. The maximum amount of the grant is reduced pro rata temporis for proposals of shorter duration. Additional funding is not subject to pro rata temporis reduction for projects of shorter duration. Both the…

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…

Expected Impact: The action under this topic is expected to achieve the following impacts: Faster and more informed decision-making through the use of an AI-driven NAM (AI Foundation Toxicology Model) and increased efficiency through rapid processing of vast amounts of data [1] . Increased consistency and standardisation in a NAM-based approach, specifically an AI model, used by industry in the efficient development, testing and production of safe and effective innovative health technologies, improving industrial competitiveness. Regulatory adoption of a NAM-enabled second species waiver model (AI Foundation Toxicology Model) and weight-of-evidence framework, in line with recommendations and more consistent global decision-making on waiving second species testing. Reduction in animal use, accelerated timelines and lower costs, enhancing the competitiveness of the European health industry through economical and ethical benefits. Improved public health as patients will benefit from safe and effective medicines developed faster using validated NAMs. The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and…

Expected Outcome: Successful proposals will contribute to the Chemicals Strategy for Sustainability and Ecodesign for Sustainable Products Regulation, the Chemical Industry Action Plan, the Clean Industrial Deal as well as the Horizon Europe Mission "Restore our Ocean and Waters by 2030" in particular to Objective 2: "Prevent and eliminate pollution of our oceans, Seas and waters". Projects results are expected to contribute to the following expected outcomes: Full industrial scale biorefinery and related value chain(s) to produce SSbD bio-based solutions for home and/or personal care sector with significantly improved sustainability. Wider availability of bio-based products in home and/or personal care sector meeting both regulatory standards and technical performance requirements. Increased consumer/end user acceptance of bio-based solutions, facilitating market uptake. Contribution to the EU strategic autonomy, resilience and competitiveness, reducing the fossil feedstock dependence for chemicals production and minimising biomass imports dependencies. Scope: The home and personal care sector, including fast-moving consumer goods (FMCG) and cosmetics, is a key industry where…